tert-butyl (S)-N-{2-[(2-amino-1-benzyl-2-oxoethyl)amino]-2-oxoethyl}carbamate | 33900-05-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (S)-N-{2-[(2-amino-1-benzyl-2-oxoethyl)amino]-2-oxoethyl}carbamate
• 英文别名: (tert-butyloxycarbonyl)-glycyl-L-phenylalanine amide；N-tert-butyloxycarbonylglycyl-L-phenylalanine amide；tert-butyloxycarbonylglycylphenylalaninamide；Boc-Gly-Phe-NH2；N-(tert-Butoxycarbonyl)glycyl-L-phenylalaninamide；tert-butyl N-[2-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]carbamate
• CAS: 33900-05-9
• 化学式: C₁₆H₂₃N₃O₄
• 分子量: 321.376
• InChiKey: JUVDZQBRGRKQRP-LBPRGKRZSA-N

物化性质

• 沸点：
  602.3±55.0 °C(Predicted)
• 密度：
  1.173±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  111
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (S)-N-{2-[(2-amino-1-benzyl-2-oxoethyl)amino]-2-oxoethyl}carbamate 在 三氟乙酸 作用下， 反应 5.0h， 生成 Gly-Phe-NH2
  参考文献：
  名称：

  DTDTPA配合物的新苄基取代衍生物的弛豫性和金属转移稳定性

  摘要：

  在寻找具有更高弛豫度和选择性的新型特殊造影剂的过程中，我们准备了两种新型的苄基官能化的DTPA（“二亚乙基三胺五乙酸盐”）g配合物（S）-3和（R，S）-4，并对其进行了比较。具有与已知的区域异构体（S）-2和（S）-1相同的性质。所述的降低的横向弛豫率的理论拟合17 H的O形核2 ø得到的水的滞留时间值（τ中号）在310 K时为86–143 ns，该值并不限制质子在体温下的弛豫性。1个H-NMRD（核磁松弛分散体）概况表明的弛豫1 - 4（- [R 1 = 4.3-5.1小号-1 毫-1在20兆赫和310 K）比用于GdDTPA母体化合物更高5。过渡金属化评估表明，除（S）-2外，所有取代的化合物都比5更稳定。配合物3、1和4对Zn 2+诱导的金属转移具有最高的稳定性（以降序排列）。显然，分别在位置5、4和2的苄基取代基的空间位阻有利地降低了Zn离子的可及性。从合成的观点来看，类型1的4

  DOI：

  10.1002/hlca.200490098
• 作为产物：
  描述：

  2-(叔丁氧羰基氧亚氨基)-2-苯乙腈 在 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 水 、 乙腈 为溶剂， 反应 100.0h， 生成 tert-butyl (S)-N-{2-[(2-amino-1-benzyl-2-oxoethyl)amino]-2-oxoethyl}carbamate
  参考文献：
  名称：

  DTDTPA配合物的新苄基取代衍生物的弛豫性和金属转移稳定性

  摘要：

  在寻找具有更高弛豫度和选择性的新型特殊造影剂的过程中，我们准备了两种新型的苄基官能化的DTPA（“二亚乙基三胺五乙酸盐”）g配合物（S）-3和（R，S）-4，并对其进行了比较。具有与已知的区域异构体（S）-2和（S）-1相同的性质。所述的降低的横向弛豫率的理论拟合17 H的O形核2 ø得到的水的滞留时间值（τ中号）在310 K时为86–143 ns，该值并不限制质子在体温下的弛豫性。1个H-NMRD（核磁松弛分散体）概况表明的弛豫1 - 4（- [R 1 = 4.3-5.1小号-1 毫-1在20兆赫和310 K）比用于GdDTPA母体化合物更高5。过渡金属化评估表明，除（S）-2外，所有取代的化合物都比5更稳定。配合物3、1和4对Zn 2+诱导的金属转移具有最高的稳定性（以降序排列）。显然，分别在位置5、4和2的苄基取代基的空间位阻有利地降低了Zn离子的可及性。从合成的观点来看，类型1的4

  DOI：

  10.1002/hlca.200490098

文献信息

• Carboxyl-modified amino acids and peptides as protease inhibitors
  作者：Stewart A. Thompson、Peter R. Andrews、Robert P. Hanzlik

  DOI：10.1021/jm00151a018

  日期：1986.1

  mM, and k2 = 0.015 and 0.010 s-1, respectively). Inhibition of DPP-I by 3d provides only the second example of a cysteine protease which is strongly inhibited by a nitrile analogue of a specific substrate. Further studies are needed to determine the generality and potential utility of this finding. Compounds 3e, 3f, and 4e exemplify a new class of specific affinity labels for cysteine proteases whose

  制备几种类型的羧基修饰的氨基酸和肽，它们具有适合于几种代表性蛋白酶之一的N末端修饰（载体片段），并评估了它们对这些酶的抑制作用。羧基修饰（抑制单元）包括（b）CONH 2，（c）CSNH 2，（d）CN，（e）反式-CH ＝ CHCO 2 Me和（f）反式-CH ＝ CHSO 2 Me。载体片段包括NH2（PhCH2）CHX（1），AcNH（PhCH2）CHX（2），H2NCH2CONH（PhCH2）CHX（3）和AcNH（PhCH2）CHCONHCH2X（4）。化合物1b，1d，1e和1f是微粒体和胞质亮氨酸氨基肽酶的竞争性抑制剂（前者的Ki分别为14.8、67、61和3.7 mM，后者分别为14.1、26.4、27.3和8.8 mM） 。化合物1c和亮氨酸硫代酰胺均对这两种酶均无任何可检测的作用。化合物2b-f还是胰凝乳蛋白酶的竞争性抑制剂（Ki分别为13.9、23.0、5.3、30.8和29
• Polypeptides. Part XII. The preparation of 2-pyridyl esters and their use in peptide synthesis
  作者：A. S. Dutta、J. S. Morley

  DOI：10.1039/j39710002896

  日期：——

  amino-acid derivatives, and hydroxy-compounds) than the corresponding p-nitrophenyl esters. Evidence is presented that they are likely to be particularly useful in solid-phase peptide synthesis, and in the synthesis of O-peptides and depsipeptides.

  2-吡啶基的酯ñ -酰基氨基羧酸可从羧酸，2-羟基吡啶，并准备NN（仅“在吡啶-dicyclohexylcarbodi酰亚胺ñ在乙腈或二氯甲烷中形成-acylureas）。所述Ñ -t丁氧基-羰基-氨基甲酸2-吡啶基酯是大多结晶的，稳定的，并且在非极性溶剂相当对亲核试剂（胺，氨基-酯和酰胺更具反应性的，受阻氨基酸衍生物，和羟基化合物）比相应的对硝基苯酯。证据表明，它们可能在固相肽合成以及O肽和depsipeptide的合成中特别有用。
• Preparation of optically pure monoacyl 2-alkyl gem-diamines from peptide amides
  作者：Peter Pallai、Murray Goodman

  DOI：10.1039/c39820000280

  日期：——

  The treatment of peptide amides with [bis(trifluoroacetoxy)iodo]benzene yields monoacyl 2-alkyl gem-diamines of high optical purity as determined by reverse-phase h.p.l.c.

  与肽酰胺的治疗[双（三氟乙酰氧基）碘]苯的产率单酰基2-烷基宝石高光学纯度的-diamines如通过反相HPLC测定
• Synthesis and binding affinities of analogs of cholecystokinin-(30-33) as probes for central nervous system cholecystokinin receptors
  作者：David C. Horwell、Andrew Beeby、Colin R. Clark、John Hughes

  DOI：10.1021/jm00387a027

  日期：1987.4

  CCK-30-33 has been identified as the minimum fragment of CCK with nanomolar affinity for the central CCK receptors, as assayed by displacement of [3H]-Boc-beta-alanyl-CCK-30-33 (pentagastrin) in homogenized mouse cerebral cortex. Examination of binding using this assay in the two series Boc-Trp-X-Phe-NH2 when X = Met-Asp (Boc-CCK-30-33), Gly-Asp, Met-Gly, and Gly-Gly and when X = (CH2)n (n = 0-4) reveals that modification of the tetrapeptide reduces affinity to a maximum of micromolar affinity (Boc-Trp-Gly-Asp-Phe-NH2; Ki = 2 X 10(-6) M), whereas in the series when n = 0 and 2 pentamolar affinity is still retained (Boc-Trp-Phe-NH2, Ki = 7 X 10(-5) M; Boc-Trp NH CH2-CH2-CO-Phe-NH2, Ki = 3 X 10(-5) M). Modification of the tetrapeptide CCK-30-33 reduces affinity 1000-fold, whereas di- and tripeptide fragments are identified that reduce affinity only a further 10-fold. This structure-activity relationship establishes a basis to design "peptoid" analogues of CCK that have therapeutic potential.
• Partially Modified Retro-Inverso Pseudopeptides as Non-natural Ligands for the Human Class I Histocompatibility Molecule HLA-A2
  作者：Gilles Guichard、Francine Connan、Roland Graff、Marina Ostankovitch、Sylviane Muller、Jean-Gérard Guillet、Jeannine Choppin、Jean-Paul Briand

  DOI：10.1021/jm9509511

  日期：1996.1.1

  Syntheses of a series of partially modified retro-inverso analogues of the antigenic peptide M58-66 derived from the influenza virus matrix protein are reported. The retro-inverso modification Psi(NH-CO) was obtained by replacement of two successive amino acid residues with a 2-substituted malonate derivative and gem-diaminoalkyl residue. The resulting compounds 1-8 were tested for their binding to the human histocompatibility class I molecule HLA-A2 in an assembly assay using lysates of peptide transporter-deficient cells T2. Specific peptide-dependent HLA-A2 assembly was revealed by an enzyme-linked immunosorbent assay. Significant HLA-A2 assembly was detected in the presence of analogues [gGly(58)-(S)mLeu(59)]-M58-66 (1a), [gGly(61)-(R,S)mPhe(62)]M58-66 (4), [gVal(63)-(R,S)mPhe(64)]M58-66 (6), and [gPhe(64)-(R,S)mAla(65)]M58-66 (7). The introduction of the retro-inverso modification between P2-P3, P3-P4, P5-P6, and P8-P9 (compounds 2, 3, 5, and 8, respectively) however led to a dramatic reduction in peptide binding to HLA-A2. Interestingly, compound 1a which contains modification between P1-P2 was found to be the most potent analogue, being able to retain the original HLA-A2 binding profile of the parent peptide M58-66. Taken together, these results and recent binding data obtained in the context of murine MHC class I molecule H-2K(d) suggest that the incorporation of peptide bond surrogates in MHC class I-restricted epitopes is a useful approach to design molecules having both increased stability and high MHC-binding capacity. Depending on their agonist or antagonist effects at the T-cell receptor, such non-natural MHC ligands are likely to find many applications in the development of peptide-based vaccines or as potential therapeutic agents in the treatment of allergies and autoimmune diseases.